INVITRO TOXICITY OF 3'-AZIDO-3'-DEOXYTHYMIDINE, CARBOVIR AND 2',3'-DIDEHYDRO-2',3'-DIDEOXYTHYMIDINE TO HUMAN AND MURINE HEMATOPOIETIC PROGENITOR CELLS

被引:25
作者
DU, DL
VOLPE, DA
GRIESHABER, CK
MURPHY, MJ
机构
[1] HIPPLE CANC RES CTR,4100 S KETTERING BLVD,DAYTON,OH 45439
[2] NCI,BETHESDA,MD 20892
关键词
D O I
10.1111/j.1365-2141.1992.tb04555.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The myelotoxicities of three antiretroviral agents, 3'-azido-3'-deoxythymidine (AZT), carbovir (CBV) and 2',3'-didehydro-2',3'-dideoxythymidine (d4T), were evaluated in vitro with normal human and murine haematopoietic progenitor cells. These studies demonstrated that continuous AZT exposure was more inhibitory to human and murine colony formation than 1 h exposure, with murine and human progenitors similarly inhibited by continuous AZT exposure. These in vitro results on AZT's myelotoxicity correlate with both human and murine in vivo studies. CBV was only moderately toxic to human and murine cells following either 1 h or continuous exposure, with human and murine progenitors similarly suppressed by continuous CBV exposure. 1 h d4T exposure was less toxic to both human and murine marrow cells than continuous exposure and both species were equivalently inhibited when continuously exposed to d4T. In general, CBV was the least toxic agent to human and murine haematopoietic cells and AZT the most toxic. The study establishes CBV and d4T as less myelotoxic agents to human and murine haematopoietic progenitor cells in vitro than AZT which therefore could be considered as alternatives to AZT for the treatment of HIV infection.
引用
收藏
页码:437 / 445
页数:9
相关论文
共 39 条
  • [31] SOMMADOSSI JP, 1989, MOL PHARMACOL, V36, P9
  • [32] SOMMADOSSI JP, 1987, ANTIMICROBIAL AGENTS, V31, P192
  • [33] ACQUIRED IMMUNE-DEFICIENCY SYNDROME AND PANCYTOPENIA
    SPIVAK, JL
    SELONICK, SE
    QUINN, TC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1983, 250 (22): : 3084 - 3087
  • [34] POTENT AND SELECTIVE ACTIVITY OF A NEW CARBOCYCLIC NUCLEOSIDE ANALOG (CARBOVIR-NSC-614846) AGAINST HUMAN IMMUNODEFICIENCY VIRUS INVITRO
    VINCE, R
    HUA, M
    BROWNELL, J
    DALUGE, S
    LEE, FC
    SHANNON, WM
    LAVELLE, GC
    QUALLS, J
    WEISLOW, OS
    KISER, R
    CANONICO, PG
    SCHULTZ, RH
    NARAYANAN, VL
    MAYO, JG
    SHOEMAKER, RH
    BOYD, MR
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1988, 156 (02) : 1046 - 1053
  • [35] UTILITY OF HUMAN BONE-MARROW OBTAINED INCIDENTAL TO ORTHOPEDIC-SURGERY FOR HEMATOPOIETIC CLONAL ASSAYS
    VOLPE, DA
    DU, DL
    POHL, KP
    CAMPBELL, JP
    MURPHY, MJ
    [J]. PATHOBIOLOGY, 1991, 59 (01) : 53 - 56
  • [36] WEIDNER D A, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P418
  • [37] WEIDNER DA, 1990, MOL PHARMACOL, V38, P797
  • [38] COMPARISON OF THE EFFECT OF CARBOVIR, AZT, AND DIDEOXYNUCLEOSIDE TRIPHOSPHATES ON THE ACTIVITY OF HUMAN IMMUNODEFICIENCY VIRUS REVERSE-TRANSCRIPTASE AND SELECTED HUMAN POLYMERASES
    WHITE, EL
    PARKER, WB
    MACY, LJ
    SHADDIX, SC
    MCCALEB, G
    SECRIST, JA
    VINCE, R
    SHANNON, WM
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 161 (02) : 393 - 398
  • [39] YARCHOAN R, 1988, LANCET, V1, P76